Pomegra
Resect AI raised $25M to deploy a patented in-stream layer that detects and corrects LLM hallucinations inside the model before any response reaches users.
- Resect AI raised $25M from undisclosed private equity investors on September 3, 2026, emerging from an undisclosed stealth period.
- Its patented technology intervenes inside a model's decision-making process rather than evaluating outputs after the fact.
- Target sectors include publishing, finance, healthcare, research, and education - verticals where a fabricated fact carries explicit liability.
Washougal's Bet on AI Accountability
Resect AI, headquartered in Washougal, Washington - a small city roughly 20 miles east of Portland - exited stealth on September 3, 2026, with $25 million from private equity investors. No lead investor was named. No valuation was attached. What the company did disclose: a patented in-stream technology it calls an "accountability layer" for large language models, and a hiring plan targeting 50 employees by the end of 2026, drawing from the Seattle and Portland labor markets.
The company was co-founded by Kevin Owens as CEO, Tim Walton as Chief AI Officer, Tyler Gerber as COO, and Tommy Lofgren as Chief Product and Marketing Officer. Owens framed the company's mission plainly: "AI must be anchored in truth to be widely adopted across the enterprise." The statement positions Resect directly against a prevailing argument from frontier AI developers that hallucination rates are declining fast enough to be a solvable problem rather than a structural one.
How Does Resect AI's Technology Actually Work?
The core technical claim is intervention inside the model during inference, not around it afterward. Most hallucination-mitigation tools operate as wrappers: they receive a model's completed output, run it through a separate classifier or retrieval check, and flag or block suspicious text. Resect's approach bypasses that step entirely.
The company describes its system as injecting probes into the model's internal activations during the generation process. When those probes detect signals consistent with fabrication, corrective algorithms modify model behavior before any output is produced. Nothing gets written to the response. The platform is model-agnostic by design and connects to any LLM via API, which matters for enterprise customers that run multiple models across different workflows.
The technical distinction carries commercial weight. Post-hoc detection adds latency and introduces a second failure mode - the classifier that reviews the output can itself be wrong. In-stream correction, if it performs at commercial scale as described, avoids both problems. The patents will matter: if the method can be reproduced without them, the moat is thinner than the press release implies.
The company also ships an open-source base alongside its enterprise product suite - a common distribution play for infrastructure startups that trades early margin for developer adoption and ecosystem lock-in.
Why Is This Space Attracting Capital Now?
Enterprise AI adoption has stalled in high-stakes verticals specifically because hallucination rates remain commercially unacceptable. Published evaluations have put fabrication rates for frontier models anywhere from 3% to 27% depending on task complexity and domain. For legal services, healthcare documentation, and financial research, any rate above near-zero is enough to block deployment. A single invented citation or fabricated data point carries audit risk, potential liability, and reputational cost.
Resect's stated target sectors share a common trait: the cost of a wrong answer is explicit, traceable, and in some cases legally actionable. That specificity separates the company's pitch from the broader responsible AI category, which has drawn substantial venture interest over the past two years but produced relatively few enterprise contracts at scale. Resect is not arguing for safer AI in the abstract - it is arguing that it can make existing models factually reliable for industries that have no tolerance for the alternative.
The competitive field includes retrieval-augmented generation frameworks, constitutional AI methods from frontier labs, and a growing cohort of output-monitoring startups. None of those, Resect argues, intervene at the inference layer.
What the Round Does Not Say
The absence of a named lead investor is unusual at this funding size. Most $25 million technology rounds feature at least one institutional backer willing to attach their name - that name anchors follow-on conversations and signals market conviction. Choosing to disclose only "private equity investors" without further identification leaves open questions about deal structure, any control provisions attached, and what the fund's thesis implies about Resect's expected trajectory.
Valuation is also undisclosed. Since the company operated entirely in stealth before this announcement, there is no prior round to benchmark against - so the implied markup from seed to Series A, whenever that happens, starts from an undefined floor.
Outlook
Resect AI enters the market at a moment when the cost of AI error has moved from theoretical to measurable for a growing number of enterprise buyers. A $25M raise supports go-to-market buildout and an engineering team capable of credible pilots, but this is infrastructure business - adoption tends to compound slowly before it scales quickly. The durability of Resect's position depends on two things the funding announcement cannot confirm: whether the patents hold under technical scrutiny, and whether in-stream correction at commercial deployment speeds performs as described. Both will become clear in the next 12 to 18 months as the company moves from stealth-mode claims to auditable enterprise deployments.
